Cargando…
PCSK9 inhibitors – from discovery of a single mutation to a groundbreaking therapy of lipid disorders in one decade
Hypercholesterolemia is one of the main risk factors for coronary heart disease and significantly contributes to the high mortality associated with cardiovascular diseases. Statin therapy represents the gold standard in the reduction of low-density lipoprotein cholesterol concentration. Nevertheless...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Termedia Publishing House
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5510512/ https://www.ncbi.nlm.nih.gov/pubmed/28721159 http://dx.doi.org/10.5114/aoms.2017.65239 |